CureVac N.V.’s (NASDAQ: CVAC) Chief Monetary Officer Pierre Kemula is optimistic its COVID-19 vaccine might nonetheless be supplied to sure age teams or as a booster, the Monetary Instances reported on Thursday.
What Occurred: Kemula informed FT the German vaccine developer continues to be hopeful the jab may very well be supplied to sure age teams or as a booster after knowledge from CureVac’s late-stage trial of its worldwide first-generation vaccine candidate confirmed that it had solely 47% efficacy.
“There’s quite a lot of want for vaccines on the market,” Kemula stated, including it would work with the businesses to discover a “candy spot” for the vaccine utilization, as per the report.
Why It Issues: Expectations have been operating excessive for CureVac, wherein the German authorities purchased a 23% stake to allay issues it might transfer to america. CureVac’s vaccine program disappointment comes at a time when a handful of